Cargando…

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls

OBJECTIVE: To estimate risks for all‐cause mortality and for severe COVID‐19 in multiple sclerosis patients and across relapsing–remitting multiple sclerosis patients exposed to disease‐modifying therapies. METHODS: We conducted a Swedish nationwide population‐based multi‐register linkage cohort stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longinetti, Elisa, Bower, Hannah, McKay, Kyla A, Englund, Simon, Burman, Joachim, Fink, Katharina, Fogdell‐Hahn, Anna, Gunnarsson, Martin, Hillert, Jan, Langer‐Gould, Annette, Lycke, Jan, Nilsson, Petra, Salzer, Jonatan, Svenningsson, Anders, Mellergård, Johan, Olsson, Tomas, Piehl, Fredrik, Frisell, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463950/ https://www.ncbi.nlm.nih.gov/pubmed/35993445 http://dx.doi.org/10.1002/acn3.51646

Ejemplares similares

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
por: Fink, Katharina, et al.
Publicado: (2023)

Risk of depression in multiple sclerosis across disease-modifying therapies
por: Longinetti, Elisa, et al.
Publicado: (2021)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
por: Alping, Peter, et al.
Publicado: (2019)

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
por: Novakova, Lenka, et al.
Publicado: (2017)

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
por: Starvaggi Cucuzza, Chiara, et al.
Publicado: (2022)

Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse
por: McKay, Kyla A., et al.
Publicado: (2022)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary
por: Lycke, Jan, et al.
Publicado: (2022)

Determinants of quality of life in pediatric- and adult-onset multiple sclerosis
por: McKay, Kyla A., et al.
Publicado: (2020)

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
por: Barker, Steven A.
Publicado: (2022)

Rituximab, MS, and pregnancy
por: Smith, Jessica B., et al.
Publicado: (2020)

Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka
por: Gamage, S. M. K., et al.
Publicado: (2018)

Association between brain volume and disability over time in multiple sclerosis
por: Moridi, Thomas, et al.
Publicado: (2022)

Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis
por: Link, Jenny, et al.
Publicado: (2014)

Long-term disability progression of pediatric-onset multiple sclerosis
por: McKay, Kyla A., et al.
Publicado: (2019)

Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study
por: Smith, Kelsi A, et al.
Publicado: (2023)

DMT Models the Near-Death Experience
por: Timmermann, Christopher, et al.
Publicado: (2018)

DMT alters cortical travelling waves
por: Alamia, Andrea, et al.
Publicado: (2020)

Regulation of DMT1 on autophagy and apoptosis in osteoblast
por: Liu, Fei, et al.
Publicado: (2017)

Correction: DMT alters cortical travelling waves
por: Alamia, Andrea, et al.
Publicado: (2020)

Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis
por: Longinetti, Elisa, et al.
Publicado: (2017)

Inflammation-related plasma and CSF biomarkers for multiple sclerosis
por: Huang, Jesse, et al.
Publicado: (2020)

Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study
por: McKay, Kyla A., et al.
Publicado: (2021)

Neural correlates of the DMT experience assessed with multivariate EEG
por: Timmermann, Christopher, et al.
Publicado: (2019)

Neural network models for DMT-induced visual hallucinations
por: Schartner, Michael M, et al.
Publicado: (2020)

CPT—DMT Correlations on Regional Soils from Croatia
por: Grabar, Kristijan, et al.
Publicado: (2022)

Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis
por: Åkesson, Julia, et al.
Publicado: (2023)

Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study
por: Binzer, Stefanie, et al.
Publicado: (2019)

The Expression of VEGF-A Is Down Regulated in Peripheral Blood Mononuclear Cells of Patients with Secondary Progressive Multiple Sclerosis
por: Iacobaeus, Ellen, et al.
Publicado: (2011)

Inflammatory activity and vitamin D levels in an MS population treated with rituximab
por: Linden, Johan, et al.
Publicado: (2019)

The DQB1(*)03:02 Genotype and Treatment for Pain in People With and Without Multiple Sclerosis
por: Burkill, Sarah, et al.
Publicado: (2020)

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
por: Vågberg, M., et al.
Publicado: (2016)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study
por: He, Anna, et al.
Publicado: (2023)

Regulation of DMT1 on Bone Microstructure in Type 2 Diabetes
por: Zhang, Wei-Lin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dsgvo7j8t94ci9pk8avr09u4k0